I had a look for patients using rasagiline, isadiprine, ... to see whether I could see some obvious signs of neuroprotectiveness of these meds. I have to say it really is a mess. Every patient has a complete different progression graph. Some patients have slow progression almost without any medication, others take a lot of meds and progress fast, others take meds and progress slowly, ... I really wonder how clinical trials can say anything at all about disease progression. As long as there are no biomarkers, all these clinical trials are a waste of money.